Neomed Management

Neomed Management AS is a prominent Norwegian venture capital firm headquartered in Oslo, specializing in early-stage life science companies. Established with a clear mandate to foster innovation in healthcare, the firm primarily invests in therapeutics, medical devices, and diagnostics. Their investment strategy centers on identifying companies with a robust scientific foundation and a well-defined path to market, aiming to support the development of groundbreaking medical solutions.

As an early-stage investor, Neomed Management typically engages with companies from their seed phase through Series A and B rounds. The firm is known for its hands-on approach and long-term commitment, often participating in subsequent funding rounds to support portfolio companies through critical development milestones, including clinical trials and market entry. Neomed frequently co-invests alongside other venture capital firms, corporate partners, and strategic investors, leveraging a broader network and capital base to accelerate growth.

Neomed Management boasts a strong track record of backing successful life science ventures, many of which have achieved significant milestones such as public listings or strategic acquisitions. Notable examples from their portfolio include Nykode Therapeutics (formerly Vaccibody), a clinical-stage immunotherapy company that successfully raised approximately NOK 700 million (around $75 million) in its 2020 Euronext Growth Oslo IPO. Another key investment, CardioMech, a medical device company, secured a $15 million Series A funding round in 2020, with Neomed's participation. The firm's strategic investments have contributed to advancing promising technologies and bringing innovative healthcare solutions to market, solidifying its reputation as a key player in the Nordic life science investment landscape.